Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor

Functional selectivity is well established as an underlying concept of ligand-specific signaling via G protein-coupled receptors (GPCRs). Functionally, selective drugs could show greater therapeutic efficacy and fewer adverse effects. Dual coupling of the β 2 -adrenoceptor (β 2 AR) triggers a signal...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology Vol. 388; no. 1; pp. 51 - 65
Main Authors: Reinartz, Michael T., Kälble, Solveig, Littmann, Timo, Ozawa, Takeaki, Dove, Stefan, Kaever, Volkhard, Wainer, Irving W., Seifert, Roland
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-01-2015
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Functional selectivity is well established as an underlying concept of ligand-specific signaling via G protein-coupled receptors (GPCRs). Functionally, selective drugs could show greater therapeutic efficacy and fewer adverse effects. Dual coupling of the β 2 -adrenoceptor (β 2 AR) triggers a signal transduction via G s α and G i α proteins. Here, we examined 12 fenoterol stereoisomers in six molecular and cellular assays. Using β 2 AR-G s α and β 2 AR-G i α fusion proteins, ( R , S’ )- and ( S , S’ )-isomers of 4′-methoxy-1-naphthyl-fenoterol were identified as biased ligands with preference for G s . G protein-independent signaling via β-arrestin-2 was disfavored by these ligands. Isolated human neutrophils constituted an ex vivo model of β 2 AR signaling and demonstrated functional selectivity through the dissociation of cAMP accumulation and the inhibition of formyl peptide-stimulated production of reactive oxygen species. Ligand bias was calculated using an operational model of agonism and revealed that the fenoterol scaffold constitutes a promising lead structure for the development of G s -biased β 2 AR agonists.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0028-1298
1432-1912
DOI:10.1007/s00210-014-1054-5